ArticleInternational journal of hepatology2025
Studying the Effect of Hepatic Steatosis on Liver Stiffness Measurement (LSM) in HBV Patients With and Without Therapy.
Article in International journal of hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The issue of fatty liver disease is becoming more widely acknowledged as a global health concern. This disorder manifests as inflammation brought on by varied degrees of fat buildup in the liver tissue. Since studies have shown that fatty liver is a major factor affecting the prognosis of patients with chronic hepatitis, the coexistence of viral hepatitis and fatty liver is noteworthy. Transient elastography is a useful technique for identifying and measuring the degree of steatosis. The liver stiffness measurement (LSM) index might be a good substitute for these patients if it shows a high diagnostic value in identifying hepatic steatosis. Methods: This pilot study presents an analytical cross-sectional analysis of 53 hepatitis B patients (26 men and 27 women) who sought care at Aria Hospital in Ahvaz, Iran, between April 2023 and November 2024. Participants were divided into two groups: 34 patients in the treatment group and 19 patients in the nontreatment group. The subjects' prevalence of hepatic fibrosis was evaluated using transient elastography and the LSM index. Further comparisons between treatment-receiving and nonreceiving patients were conducted using LSM. Results: The prevalence of steatosis was found to be 25% in the untreated group and 26.7% in the treatment group. In the treatment group, the incidence of fibrosis was 58.8%, while in the untreated group, it was 57.9%. In both the treatment-treated and nontreated groups of hepatitis B patients, the associations between the study variables and the LSM index were evaluated. Every correlation that was found was not statistically significant. Additionally, the LSM's diagnostic value for hepatic steatosis was evaluated. In the treatment group, the test showed limited diagnostic value, while in the untreated group, it showed satisfactory diagnostic value. Conclusions: In patients with hepatitis B, the LSM derived from transient elastography does not show a statistically significant correlation with factors such as age, gender, body mass index (BMI), or degree of hepatic steatosis. According to this study, the LSM number is not a reliable indicator for identifying hepatic steatosis in patients with hepatitis B when compared to the CAP score (AUC = 0.69 and 0.74).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.